Bangladesh Everest version of Lorlatinib

Lorlatinib is a tyrosine kinase inhibitor that belongs to the third generation of ALK (tyrosine kinase) and ROS1 (ROS proto-oncogene 1) inhibitor, mainly used to treat lung cancer with ALK or ROS1 gene mutations in patients with non-small cell lung cancer (NSCLC).

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. Please consult the local hospital pharmacy for details. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same. Bangladesh Everest version of LorlatinibGeneric drug specification100mg*30It is about 5,000 yuan.

What is unique about this drug is its broad inhibitory spectrum, able to combat some ALK and ROS1 mutations that are not covered by other therapeutics. By inhibiting the activity of these genes, lorlatinib blocks the conduction of abnormal signaling pathways and slows down the growth and spread of tumor cells.

Larlatinib is commonly used as a first-line treatment option for patients with ALK-positive NSCLC, especially those who have developed resistance to other ALK inhibitors. In addition, it can also be used for the treatment of ROS1positive NSCLC.

Clinical trial data show that lorlatinib shows significant efficacy in the treatment of lung cancer patients with specific genetic mutations. Due to its potent inhibitory effect and broad spectrum applicability, lorlatinib offers new hope to some patients, especially in the face of limited or resistant other treatment options.

However, like all drugs, lorlatinib may also cause some side effects, including but not limited to fatigue, nausea, vomiting, high blood pressure, etc. Therefore, when using lorlatinib, doctors carefully evaluate the patient's overall health and develop the most appropriate treatment plan based on the individual situation.